Aventis growth driven by strong US pharmaceutical sales
Franco-German group Aventis reports that net income for the first ninemonths of 2001 reached 1.12 billion euros ($1.01 billion), compared with 463 million euros in the like, year-earlier period (or 947 million euros before exceptionals). Sales were up 2.9% to 17.00 billion euros, and the company noted that these figures include the contributions of non-core businesses such as Aventis CropScience, which has been sold to Bayer for $1.5 billion euros (Marketletters passim). Earnings per share went up from 0.59 euros to 1.43 euros.
Aventis Pharma reported sales of 12.96 billion euros, a rise of 14.4% excluding currency and structural effects, with net income for the division climbing 42.7% to 1.15 billion euros. Pharmaceutical turnover in the USA increased 25.9% to 4.66 billion euros, while Japanese sales were up 12.2% to 817 million euros.
Allegra still selling well
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze